Clinical Trials Logo

Filter by:
NCT ID: NCT03853174 Completed - COPD Clinical Trials

Exercise Training and Inflammatory Mediators in COPD

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Chronic obstructive pulmonary disease (COPD) is widely spread all over the world. It is predicted to be the third leading cause of death by 2020[1]. COPD is a common, preventable treatable disease that is characterized by an airflow limitation which is not fully reversable[2].

NCT ID: NCT03831204 Completed - Heart Failure Clinical Trials

Systolic Time Intervals a Prognostic Tool of Heart Failure in Emergency Departement (STI/AHF)

Start date: February 20, 2017
Phase:
Study type: Observational

The performance of STIs and clinical scores alone and their combination to predict short term prognosis of acute decompensated heart failure.

NCT ID: NCT03830359 Completed - Dry Eye Syndrome Clinical Trials

Efficacy, Safety of T2769 in Dry Eye Disease

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

Efficacy of T2769 in Dry Eye Desease

NCT ID: NCT03806972 Completed - Acute Heart Failure Clinical Trials

Short and Long Term Prognosis of Patients Admitted to the ED With Acute Heart Failure

CRF
Start date: June 1, 2009
Phase:
Study type: Observational [Patient Registry]

Heart failure (HF) is the leading cause of hospitalization ,rehospitalization and mortality for adults over 65 years of age. This study aimed to assess mortality, and hospitalization rates at 30 days and one year after dicharge of patients with heart failure (HF) with reduced ejection fraction (HFrEF) compared to HF with preserved ejection fraction (HFpEF).

NCT ID: NCT03802201 Completed - ß-thalassemia Clinical Trials

Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia

TRANSCEND
Start date: December 19, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2 open-label, single-arm design study with dose escalation by subject cohort . The study is designed to monitor the PTG-300 safety profile, to obtain preliminary evidence of efficacy of PTG-300 for the treatment in β-thalassemia.

NCT ID: NCT03801447 Completed - Preeclampsia Clinical Trials

Biomarkers and Preeclampsia Outcomes

REPORTS
Start date: April 1, 2018
Phase:
Study type: Observational

Prospective, observational, monocentric, non-interventional study.

NCT ID: NCT03799185 Completed - Atherosclerosis Clinical Trials

Dyslipidemia Prevalence, Perception, Treatment, and Awareness in the Tunisian Population

ATERASurvey
Start date: January 4, 2016
Phase:
Study type: Observational [Patient Registry]

ATERA Survey is a national cross sectional observational study, aiming to determine the prevalence of dyslipidemia and other conventional risk factors for CHD (Coronary Heart Disease), the relationship between environmental and lifestyle factors with dyslipidemia, the perception and the knowledge of cardiovascular risk factors by the population, and above all, to strengthen the national strategy for primary and secondary prevention against coronary heart disease.

NCT ID: NCT03793660 Completed - Clinical trials for Arthritis, Rheumatoid

Biologic National Registry

BINAR
Start date: May 23, 2018
Phase:
Study type: Observational [Patient Registry]

BINAR is an open and multicentric Tunisian national registry performed by nearly 100 rheumatologists

NCT ID: NCT03782792 Completed - Clinical trials for Generalized Pustular Psoriasis

Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

Start date: January 31, 2019
Phase: Phase 2
Study type: Interventional

To evaluate efficacy, safety, and tolerability of spesolimab (BI 655130) compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.

NCT ID: NCT03769428 Completed - Clinical trials for Postoperative Analgesia

Postoperative Analgesia in Breast Cancer Surgery: Safety and Efficiency of Ultrasound Guided Erector Spinae Plane Block

erectspinae
Start date: December 17, 2018
Phase: N/A
Study type: Interventional

Breast cancer surgery is one of the most common surgeries, due to the high incidence of breast cancer. Unfortunately, patients experience significant postoperative acute pain, placing them at risk for increased clinical morbidity and the development of disabling chronic pain which may rich up to 55% . The intensity of perioperative pain experienced by the patient is one of the best predictors of chronic pain. However, postoperative analgesia in breast cancer surgery is difficult due to the extensive nature of the surgery and the complex innervation of the breast. Several newly described regional anesthesia techniques exist to control perioperative pain, including the Paravertebral block (PVB) which has been proved to be the most effective one. The anatomic proximity of the pleura and central neuraxial system makes it a particularly challenging technique and carrying a risk of pneumothorax. The Erector Spinae Plane Block (ESPB) is a novel interfascial plane block described by Forero et al in September 2016. Local anesthetic injection is performed beneath the erector spinae muscle. Local anesthetic (LA) expected to achieve paravertebral spread of three vertebral levels cranially and four levels caudally, blocking the dorsal and ventral rami of the spinal nerves.The easy, fast and safe execution of ESPB makes it a promising technique in the context of surgical pain during breast cancer surgery. There is no sufficient randomized controlled trials that assess the effectiveness of ESPB in controlling post-operative breast surgery pain. The main purpose of this study is to evaluate the postoperative analgesic effect of Ultrasound-guided ESPB in patients undergoing breast cancer surgery.